Elite Pharmaceuticals Inc (OTCPK:ELTP)

Q1 2026 Elite Pharmaceuticals Inc Earnings Call Transcript

Aug 15, 2025 / 03:30 PM GMT

Release Date Price: $0.5425 (+2.40%)

Transcript 8-K10-Q

Key Points

Positve

Elite Pharmaceuticals Inc (ELTP) reported a significant increase in total revenues for the quarter, reaching $40.2 million, more than doubling from $18.8 million in the same quarter last year.
The company's gross profit also saw a substantial rise, reaching $27.2 million, which is a 220% increase compared to the previous year.
Elite Pharmaceuticals Inc (ELTP) has successfully established its Elite label in niche markets, contributing to its revenue growth.
The Lisex amphetamine product line has been a major contributor to the company's financial success, with high demand and a growing market share.
The company has a strong balance sheet with increasing working capital and decreasing debt, indicating financial stability.

Negative

The Lisex amphetamine market is highly competitive, leading to downward price pressure and potentially lower margins in the future.
Operating expenses have increased, particularly in professional and legal expenses due to consulting costs related to M&A projects.
Despite a strong operating income, Elite Pharmaceuticals Inc (ELTP) reported a net loss of $5.4 million due to non-cash expenses related to derivative financial instruments.
The company faces challenges in maintaining high gross profit margins due to the competitive nature of the generic pharmaceutical market.
There is uncertainty regarding the impact of potential mergers and acquisitions, with the company considering NASDAQ listing if M&A does not progress as desired.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ELTP.PK - Elite Pharmaceuticals Inc
Q1 2026 Elite Pharmaceuticals Inc Earnings Call
Aug 15, 2025 / 03:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to the Elite Pharmaceuticals first quarter of fiscal year 2026 conference call.

At this time, all lines have been placed on a listen-only mode.

Before management begins speaking, the conference has the following statement.

Elite would like to remind the listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including but not limited to statements about elites' expectations regarding forward operating results.

Forward-looking statements are made pursuant to the safe harbor provisions of their federal securities laws and represent

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.